Polypoidal choroidal vasculopathy
Conditions
Interventions
Group A:Proton radiotherapy plus anti-VEGF therapy
Group B:anti-VEGF therapy
Sponsors
Shanghai Proton and Heavy Ion Center
Eligibility
Sex/Gender
All
Age
45 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Patients willing to participate in this study and sign informed consent; 2. Aged above 45 years; 3. The eye to be treated should be: ICG confirmed as polypoidal choroidal vasculopathy; eye visual accuracy between 19 and 83 letters (20/400-20/25 in sellen visual chart); lesion not exceed macular arcus vasculosi; without optometer stroma opacity and pupil narrowing that may affect the examination of fundus; 4. The contralateral eye with visual accuracy above 19 letters (20/400 in sellen visual chart); 5. ECOG scoring 0-2.
Exclusion criteria
Exclusion criteria: 1. Disc scar invading macular fovea in the eye to be treated; 2. With diseases contraindicated by crystal contact (including corneal erosion) in the eye to be treated; 3. With other retinal diseases in the eye to be treated; 4. Ever treatment of anti-VEGF in the eye to be treated; 5. With uncontrolled glaucoma; 6. With systematic anti-VEGF therapy within 6 months; 7. With history of radiotherapy for the head and neck; 8. Participated in any other related clinical trial within 6 months; 9. Unable to follow-up in time; 10. Pregnant or lactating women; 11. Who refuse informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| best corrected visual acuity;Injection number of anti-VEGF agent; | — |
Countries
China
Contacts
Public ContactLin Kong
Shanghai Proton and Heavy Ion Center
Outcome results
None listed